Source comparison
Best Peptides for TBI Recovery: Mechanism Comparison
Cerebrolysin Mimics BDNF and NGF receptor binding to promote synaptic repair and dendritic branching in injured cortical tissue Intravenous (daily infusion) 14 human RCTs, meta-analysis shows modest functional improvement (SMD 0.34) Most established for modera
This comparison does not assign a generated winner or score.
- Cerebrolysin
- Mimics BDNF and NGF receptor binding to promote synaptic repair and dendritic branching in injured cortical tissue
- Intravenous (daily infusion)
- 14 human RCTs, meta-analysis shows modest functional improvement (SMD 0.34)
- Most established for moderate-severe TBI in European/Asian protocols
- P21
- Upregulates BDNF mRNA expression via CNTF pathway activation, increasing dendritic spine density in hippocampus
- Intranasal (bypasses BBB via olfactory pathway)
- Rodent studies only. No published human trials
- Research use for memory consolidation post-TBI
- Dihexa
- Activates HGF/c-Met signaling to restore synaptic density and cognitive function in diffuse axonal injury
- Oral (lipophilic peptidomimetic crosses BBB passively)
- Preclinical only. Rodent studies show restored spatial memory
- Experimental compound under investigation for chronic TBI
- Thymalin
- Immunomodulator. Reduces inflammatory cytokine release and supports T-cell function during acute injury phase
- Subcutaneous injection
- Limited TBI-specific data. Primarily studied in stroke and immune dysfunction
- May support acute neuroprotection but lacks neurorestorative evidence
- Professional Assessment
- Cerebrolysin has the strongest human evidence but modest effect size. P21 and Dihexa show compelling preclinical neuroplasticity effects but need phase II trials. None are FDA-approved for TBI. All use is research-based or off-label.
- .
- Select based on recovery phase: Cerebrolysin for acute-to-subacute, P21/Dihexa for chronic neuroplasticity.